{
    "persona": "conservative",
    "model": "llama2:70b-chat-q6_K",
    "topic": "healthcare",
    "language": "German",
    "text": "Encouraging results for migraine prevention with atogepant! 70% of patients achieved 50% reduction in monthly migraine days at weeks 13-16, maintained over 48 weeks. Safety and tolerability data look good too.",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "1d38e8cc0dfa1982c06a2a5b52d8af850987f0090b5f0111"
}